NASDAQ:AGLE Aeglea BioTherapeutics (AGLE) Stock Price, News & Analysis → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free AGLE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$9.47▼$13.7652-Week Range N/AVolume43,300 shsAverage Volume95,409 shsMarket Capitalization$48.64 millionP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock Analysis Get Aeglea BioTherapeutics alerts: Email Address Ad Paradigm PressWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from these levels.But there are at least 10 different coins that I like even better. About Aeglea BioTherapeutics Stock (NASDAQ:AGLE)Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Read More Ad Paradigm PressWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from these levels.But there are at least 10 different coins that I like even better. AGLE Stock News HeadlinesFebruary 21, 2024 | benzinga.comNorthwest Biotherapeutics Stock (OTC:NWBO), Analyst Ratings, Price Targets, PredictionsJanuary 30, 2024 | wsj.comBridge Biotherapeutics Inc.December 7, 2023 | finance.yahoo.comSpyre Therapeutics Announces $180 Million Private PlacementNovember 27, 2023 | msn.comAeglea Biotherapeutics announces name change to Spyre TherapeuticsNovember 27, 2023 | markets.businessinsider.comAeglea BioTherapeutics Changes Name To Spyre Therapeutics; To Begin Trading Under Symbol SYRENovember 27, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNovember 9, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 30, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming November Investor ConferencesOctober 5, 2023 | msn.comAeglea BioTherapeutics (AGLE) Price Target Increased by 2435.71% to 18.11October 2, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Grants of Inducement AwardsSeptember 14, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming September ConferenceSeptember 14, 2023 | markets.businessinsider.comAeglea Biotherapeutics (AGLE) Gets a Buy from Stifel NicolausSeptember 8, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Announces Reverse Stock SplitSeptember 7, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Reverse Stock SplitSeptember 5, 2023 | seekingalpha.comAeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLOSeptember 5, 2023 | markets.businessinsider.comAeglea BioTherapeutics Appoints Scott Burrows As Chief Financial OfficerSeptember 5, 2023 | finance.yahoo.comAeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesAugust 16, 2023 | msn.comWells Fargo Maintains Aeglea BioTherapeutics (AGLE) Equal-Weight RecommendationAugust 11, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | fool.comAeglea BioTherapeutics (NASDAQ: AGLE)August 3, 2023 | msn.comAeglea BioTherapeutics (AGLE) Price Target Decreased by 54.54% to 1.45July 27, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica PharmaJuly 25, 2023 | seekingalpha.comAeglea initiated with Buy at Stifel citing potential in IBD spaceJuly 25, 2023 | msn.comStifel Initiates Coverage of Aeglea BioTherapeutics (AGLE) with Buy RecommendationSee More Headlines Receive AGLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today6/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGLE CUSIPN/A CIK1636282 Webwww.aegleabio.com Phone(512) 942-2935Fax512-872-5121Employees69Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$22.50 Low Stock Price Target$12.50 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($75.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,820,000.00 Net Margins-22,195.36% Pretax Margin-27,931.12% Return on Equity-132.05% Return on Assets-146.87% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.59 Sales & Book Value Annual Sales$2.33 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($60.61) per share Price / BookN/AMiscellaneous Outstanding Shares4,050,000Free Float3,782,000Market Cap$48.64 million OptionableOptionable Beta2.57 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Jonathan D. Alspaugh M.B.A. (Age 40)Strategic Advisor Comp: $568.55kMr. James Paul Kastenmayer J.D. (Age 51)Ph.D., Consultant Comp: $611.84kDr. Cameron Turtle DPHIL (Age 33)Ph.D., COO & Principal Executive Officer Mr. Scott L. Burrows (Age 46)Chief Financial Officer Joey PerroneVice President of Finance & Investor RelationsMs. Heidy Abreu King-Jones J.D. (Age 40)L.L.M., Chief Legal Officer & Corporate Secretary Dr. Kelly Boothe Ph.D.Senior Director of Corporate Communications & Investor RelationsMore ExecutivesKey CompetitorsImmunicNASDAQ:IMUXIncannex HealthcareNASDAQ:IXHLRezoluteNASDAQ:RZLTInventivaNASDAQ:IVACapricor TherapeuticsNASDAQ:CAPRView All Competitors AGLE Stock Analysis - Frequently Asked Questions Should I buy or sell Aeglea BioTherapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AGLE shares. View AGLE analyst ratings or view top-rated stocks. What is Aeglea BioTherapeutics' stock price target for 2024? 2 analysts have issued twelve-month target prices for Aeglea BioTherapeutics' stock. Their AGLE share price targets range from $12.50 to $22.50. On average, they expect the company's stock price to reach $17.50 in the next twelve months. View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts. How were Aeglea BioTherapeutics' earnings last quarter? Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) posted its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($7.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.00) by $0.75. The biotechnology company earned $1.40 million during the quarter, compared to the consensus estimate of $1.38 million. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%. When did Aeglea BioTherapeutics' stock split? Aeglea BioTherapeutics shares reverse split on the morning of Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO? 3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Aeglea BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA). When did Aeglea BioTherapeutics IPO? Aeglea BioTherapeutics (AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Aeglea BioTherapeutics' major shareholders? Aeglea BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza. View institutional ownership trends. This page (NASDAQ:AGLE) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeglea BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.